Depression linked to earlier treatment intensification in T2D

For individuals with type 2 diabetes (T2D) who are initiating oral glucose-lowering monotherapy, a history of clinically diagnosed depression is associated with earlier treatment intensification, such as adding medication or switching to a new drug class, and insulin initiation, as shown in a retrospective study.

Researchers used primary care records from the Clinical Practice Research Datalink Aurum database and looked at adults with T2D initiating oral glucose-lowering monotherapy. Depression history was categorized according to the recency of episodes: recent (≤1.7 years), intermediate (1.7–12.8 years), distant (>12.8 years), or none.

The main outcomes were time to treatment intensification and insulin initiation. Royston-Parmar survival models were applied in the analyses.

A total of 378,935 participants were included in the analysis. Of these, 25.1 percent had a history of depression, and 93.6 percent were initiated on metformin. Characteristics varied across depression categories. The median age was 54.5 years in the recent depression group, 57.6 years in the intermediate depression group, 60.5 years in the no-depression group, and 63.6 years in the distant depression group. The proportion of women was higher across all depression groups (54.5 percent to 56.5 percent) but lower in the no-depression group (37.7 percent).

Compared with no prior depression, recent depression was associated with 20-percent increased odds of treatment intensification (odds ratio [OR], 1.20, 95 percent confidence interval [CI], 1.17–1.23) and 29-percent greater odds of insulin initiation (OR, 1.29, 95 percent CI, 1.23–1.36).

Intermediate and distant depression were also associated with increased odds of both outcomes, although the effect sizes were small, particularly for distant depression.

The findings underscore the importance of integrating mental and physical healthcare in diabetes management.